On November 16, 2026, Tempus AI, Inc. (the “Company”) and AstraZeneca AB (“AstraZeneca”) entered into a Fifth Amendment (the “Amendment”) to the Master Services Agreement, dated November 17, 2021, between the Company and AstraZeneca (as previously amended, the “MSA”). The Amendment, which is effective as of January 1, 2027, establishes a new five-year financial commitment period between AstraZeneca and the Company, extends the associated strategic collaborator benefits provided to AstraZeneca under the existing MSA, and extends the term of the MSA through December 31, 2031 (the “Renewal Term”), subject to further extension under certain conditions. Pursuant to the Amendment, AstraZeneca has committed to an aggregate of $200 million in fees to be paid or payable to the Company under the MSA and other agreements between the parties and their affiliates during the Renewal Term, representing an annual target spend of $40 million across the Company’s existing and future products and services. AstraZeneca has also agreed to a minimum of $32 million in such fees in each calendar year of the Renewal Term.
|
Tempus AI, Inc. is a technology company focused on precision medicine that applies artificial intelligence to healthcare diagnostics. The company operates through two primary product lines: Diagnostics and Data and applications. Its Diagnostics segment provides next-generation sequencing, PCR profiling, and molecular pathology testing for oncology and hereditary diseases, serving healthcare providers, life sciences companies, and researchers. The Data and applications segment offers products including Insights, which licenses de-identified clinical and molecular data libraries; Trials, which supports clinical trial matching; Next, an AI platform for identifying care gaps in oncology and cardiology; and Algos, which provides algorithmic diagnostics such as TO, HRD, and DPYD. Tempus utilizes a proprietary platform to integrate multimodal clinical, molecular, and imaging data, connecting over 700 data sources to support personalized therapy selection and drug discovery. The company serves physicians, pharmaceutical and biotechnology firms, and patients in the United States, leveraging a large library of clinical and molecular data to enhance diagnostic accuracy and research capabilities. Summarised from the company's own disclosures, fiscal year ended Feb 2026 |
Industry Health Information Services | Homepage tempus.com |
| Sector Healthcare | IR page tempus.com | |
|
Tags
precision medicine, artificial intelligence, genomic diagnostics, oncology, clinical trial matching, data analytics, molecular pathology, drug discovery, healthcare data integration, Tempus Platform, Insights, Next, Trials, Algos, TO, HRD, DPYD, Tempus Purist, Hub, Lens, Pixel, Foundation models, Assays, Olivia
|
Press page tempus.com/news |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 13.39B |
| Market cap (USD) | $ 13.39B |
| P/E | -70.08 |
| PEG | — |
| P/BV | 26.76 |
| P/S | 8.87 |
| P/OCF | -123.56 |
| P/FCF | -97.89 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -89.5% |
| ROI | -14.2% |
| ROIC | -11.0% |
| Profit margin | -19.3% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | Yes |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | Yes |
| Buying back stock | — |
| Diluting (TTM) | Yes |
| Debt/Equity | 252.3% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 78 |
| Quality score | -43.8% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Balance sheet detail | |||||
| Trade receivables (USD) | — | — | 94.5M | 155M | 311M |
| ↳ YoY growth | +63.9% | +101.0% | |||
| Lease liabilities (USD) | — | — | 38.5M | 32.7M | 87.6M |
| Cash and deposits (USD) | 278M | 304M | 166M | 341M | 605M |
| Intangible assets (USD) | — | — | 21.9M | 11.7M | 355M |
| Right-of-use assets (USD) | — | — | 20.5M | 14.8M | 64.5M |
| Cash flow detail | |||||
| Operating cash flow (USD) | — | -168M | -214M | -189M | -218M |
| Purchases of property, plant and equipment (USD) | — | -18.4M | -34.6M | -22.1M | -21M |
| Change in receivables (cash effect) (USD) | — | -8.2M | -7.35M | -61M | -90.4M |
| Change in inventories (cash effect) (USD) | — | -1.31M | -6.56M | -9.54M | -3.37M |
| Change in payables (cash effect) (USD) | — | -7.92M | -23.4M | -23.9M | -7.24M |
| Dividends paid (cash effect) (USD) | — | -5.63M | -5.63M | -5.63M | 0.00 |
| Interest paid (cash effect) (USD) | — | -4.66M | -16.9M | -28M | -44M |
| Income taxes paid (cash effect) (USD) | — | -6,000 | -161,000 | -206,000 | -654,000 |
| Share-based compensation (USD) | — | 0.00 | 0.00 | 534M | 125M |
| Operating cash flow before change in receivables (USD) | — | -160M | -207M | -128M | -128M |
| Free cash flow (OCF - PPE - intangibles) (USD) | — | -187M | -249M | -211M | -239M |
| Income detail | |||||
| Research and development expense (USD) | — | 83.2M | 90.3M | 149M | 173M |
| Total comprehensive income (USD) | — | -290M | -214M | -706M | -244M |
| Comprehensive income to owners (USD) | — | -290M | -214M | -706M | -244M |
| Provision for credit losses (USD) | — | 3.87M | 1.65M | 680,000 | 2.56M |
| Credit cost ratio (credit losses / average receivables) (%) | — | — | — | 0.5% | 1.1% |
| Reported | Feb 24, 2025 | Feb 24, 2025 | Feb 24, 2025 | Feb 24, 2025 | Feb 24, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
CHICAGO, November 2, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended September 30, 2026.
“Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications,” said Eric Lefkofsky, founder and CEO of Tempus. “These results reinforce the durability of our model as our best-in-class diagnostic platform enhances our data and AI offerings, distinguishes our business from our many competitors, and helps drive our performance quarter after quarter.”
Third Quarter 2026 Highlights
For the three-month period ended September 30, 2026, as compared to the same period in 2025:
• Total revenue of $411.5 million, an increase of 23%
• Oncology volume growth accelerated to 32%
• Minimal Residual Disease (MRD) volume of ~12,000 tests, up 300%
• Data & Apps revenue increased 33%, with Insights increasing 29%
• Increasing full year 2026 revenue guidance to $1.60 to $1.605 billion and expect full year Adjusted E
NEWS RELEASE
Tempus Receives IVDR Certi cation for xR RNA Sequencing for Solid Tumor Pro ling 2026-10-26 CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM) today announced that its xR assay has received certi cation under the European Union’s In Vitro Diagnostic Regulation (IVDR) as a Class C in vitro diagnostic device. The certi cation covers Tempus’ quality management system for "next-generation sequencing devices for cancer genomic pro ling to support clinical management." xR detects gene rearrangements and speci c splice variants in solid tumor tissue to support clinical management. A published study demonstrated that combining Tempus RNA and DNA testing increases detection of clinically actionable gene fusions compared with DNA testing alone. IVDR certi cation supports continued access to xR in the EU beyond 2028, the transition deadline for eligible legacy Class C devices, and provides biopharma partners with an IVDR-certi ed testing platform to support clinical studies. "Securing our European IVDR certi cation for xR reinforces our commitment to meeting the highest regulatory standards globally," said Lauren Silvis, SVP of External A airs at Tempus. "This achievement establishes a strong regulatory foundation in Europe as we work to expand access to our advanced RNA sequencing tools for healthcare providers, biopharma partners and cancer patients across the region."
About Tempus Tempus is a technology company advancing precision medicine through the practical application of arti cial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal 1
therapeutics. The goal is for each patient to bene t from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and bene ts of Tempus xR and IVDR certi cation. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forwardlooking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may a ect Tempus’ business, nancial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ nancial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the arti cial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain quali ed team members and key personnel; the ability to repay or re nance outstanding debt, or to access additional nancing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed con ict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, led with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other lings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to re ect events or circumstances after the date of this press release or to re ect new information or the occurrence of unanticipated events, except as required by law. Hanah Heintzelman [email protected] Source: Tempus AI, Inc.
2
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Sep 30, 2021 | Renamed | Tempus Labs, Inc. → TEMPUS AI, INC. |
ETFs Holding Tempus AI, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| ARKG | 9.63% | 2,761,952 | $ 175.191M | Nov 18, 2026 |
| ARKK | 5.60% | 11,201,377 | $ 710.503M | Nov 18, 2026 |
| XOVR | 2.05% | 775,100 | $ 44.902M | Jun 30, 2026 |
| HELX | 1.95% | 9,397 | $ 544.368K | Jun 30, 2026 |
| NXTE | 1.28% | 12,719 | $ 736.812K | Jun 30, 2026 |
| BCSM | 1.21% | 6,942 | $ 402.15K | Jun 30, 2026 |
| JTEK | 1.20% | 744,622 | $ 47.231M | Nov 17, 2026 |
| MKTN short | -1.09% | -20,155 | $ -1.168M | Jun 30, 2026 |
| AGIX | 1.03% | 143,881 | $ 8.335M | Jun 30, 2026 |
| BMED | 0.79% | 1,749 | $ 113.265K | Nov 16, 2026 |
| NANC | 0.60% | 24,993 | $ 1.619M | Nov 17, 2026 |
| FEMG | 0.60% | 691 | $ 40.03K | Jun 30, 2026 |
| FLDZ | 0.43% | 305 | $ 17.669K | Jun 30, 2026 |
| BAI | 0.32% | 551,443 | $ 35.711M | Nov 16, 2026 |
| TEK | 0.27% | 1,559 | $ 100.961K | Nov 16, 2026 |
| TGRT | 0.27% | 66,132 | $ 4.283M | Nov 17, 2026 |
| CLSE short | -0.17% | -24,219 | $ -1.527M | Aug 31, 2026 |
| BALQ | 0.09% | 604 | $ 39.115K | Nov 16, 2026 |
| FMDE | 0.04% | 54,730 | $ 3.171M | Jun 30, 2026 |
| ENHU | 0.04% | 52 | $ 3,367.52 | Nov 16, 2026 |
| MSSM | 0.04% | 4,237 | $ 267.143K | Aug 31, 2026 |
| IALT short | -0.02% | -24,001 | $ -1.554M | Nov 16, 2026 |
| DFUS | 0.00% | 1,390 | $ 105.487K | Nov 12, 2026 |
| DFAU | 0.00% | 368 | $ 27.928K | Nov 12, 2026 |
| DFAC | 0.00% | 1,577 | $ 119.679K | Nov 12, 2026 |
| DCOR | 0.00% | 609 | $ 46.217K | Nov 12, 2026 |
| DFSU | 0.00% | 12 | $ 910.68 | Nov 12, 2026 |
_(1).png)